Get the Stockscreener App
2.42
3.59%
-0.09
After Hours:
2.41
-0.010
-0.41%
Acumen Pharmaceuticals Inc stock is traded at $2.42, with a volume of 303.32K.
It is down -3.59% in the last 24 hours and down -5.84% over the past month.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
See More
Previous Close:
$2.51
Open:
$2.53
24h Volume:
303.32K
Relative Volume:
0.57
Market Cap:
$174.79M
Revenue:
-
Net Income/Loss:
$-121.34M
P/E Ratio:
-1.2079
EPS:
-2.0035
Net Cash Flow:
$-115.63M
1W Performance:
+11.52%
1M Performance:
-5.84%
6M Performance:
+24.10%
1Y Performance:
+137.25%
1-Day Range:
$2.38
$2.565
1-Week Range:
$2.18
$2.60
52-Week Range:
$0.9901
$3.60
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Name
Acumen Pharmaceuticals Inc
Sector
Industry
Phone
617-344-4190
Address
1210-1220 WASHINGTON STREET, NEWTON
Compare ABOS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
2.42 | 181.29M | 0 | -121.34M | -115.63M | -2.0035 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Citigroup | Buy |
| Jul-26-24 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-20-23 | Resumed | BofA Securities | Buy |
| May-18-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-15-22 | Initiated | BTIG Research | Buy |
| Jun-30-22 | Initiated | H.C. Wainwright | Buy |
| Jan-21-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-26-21 | Initiated | BofA Securities | Neutral |
| Jul-26-21 | Initiated | Credit Suisse | Outperform |
| Jul-26-21 | Initiated | Stifel | Buy |
| Jul-26-21 | Initiated | UBS | Buy |
View All
Acumen Pharmaceuticals Inc Stock (ABOS) Latest News
Acumen Pharmaceuticals (ABOS) Price Target Decreased by 20.59% to 6.88 - MSN
Acumen Pharmaceuticals Q1 2026 Earnings: Narrowed Loss Surprises as Alzheimer’s Pipeline AdvancesCapex Guidance - Newser
Acumen Pharmaceuticals (ABOS) Gains Momentum: Support Holds at $2.37, Resistance at $2.61 in FocusValue Area High - Newser
Acumen Pharmaceuticals Q1 earnings call highlights - MSN
Acumen’s Late-2026 Sabirnetug Readout Is A Viable Bet (NASDAQ:ABOS) - Seeking Alpha
Acumen Pharmaceuticals Bets Big on Alzheimer’s Trials - TipRanks
Bank of America Securities Remains a Buy on Acumen Pharmaceuticals (ABOS) - The Globe and Mail
BofA Securities Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Earnings call transcript: Acumen Pharmaceuticals beats Q1 2026 EPS forecast - Investing.com
Acumen Pharmaceuticals (ABOS) loses 33.6% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Acumen Pharmaceuticals Warns Investors: Unchanged 10-K Risk Factors Still Weigh on Valuation and Share Price - TipRanks
Acumen Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript - Sahm
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q1 2026 Earnings Call Transcript - Insider Monkey
Acumen Pharmaceuticals 1Q 2026: Net loss $(20.7)M, EPS $(0.33) — 10-Q Summary - TradingView
[10-Q] Acumen Pharmaceuticals, Inc. Quarterly Earnings Report - Stock Titan
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
TradingKey - TradingKey
Acumen expects ALTITUDE-AD top-line results in late 2026 while targeting a mid-2027 IND for 2 EBD candidates - MSN
Acumen Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Acumen Pharmaceuticals, Inc. posts first quarter financial results and reports business momentum - Traders Union
Earnings call transcript: Acumen Pharmaceuticals Q1 2026 results show EPS beat - Investing.com
Earnings call transcript: Acumen Pharmaceuticals Q1 2026 results show EPS beat By Investing.com - Investing.com South Africa
ABOS: Phase II Alzheimer's trial on track, EBD program advances, $128.4M cash supports runway into 2027 - TradingView
Acumen Pharmaceuticals Reports Q1 2026 Financial Results and Anticipates Phase 2 ALTITUDE-AD Data for Alzheimer’s Treatment - Minichart
Acumen Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Acumen Pharmaceuticals (NASDAQ:ABOS) Q1 2026 Loss Narrows as Phase 2 Alzheimer's Trial Readout Looms - ChartMill
Acumen Updates Q1 Results and Alzheimer’s Pipeline Progress - TipRanks
ACUMEN PHARMACEUTICALS ($ABOS) Releases Q1 2026 Earnings - Quiver Quantitative
Acumen Pharmaceuticals Provides Business Update and Financial Results Highlighting Phase 2 Study Progress for Alzheimer’s Treatment and Future Milestones - Quiver Quantitative
Acumen Pharmaceuticals Q1 net loss narrows - TradingView
Earnings Scheduled For May 12, 2026 - Benzinga
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights - The Manila Times
Acumen Pharmaceuticals (NASDAQ: ABOS) posts Q1 2026 loss but extends cash runway - Stock Titan
Alzheimer’s trial data slated for late 2026 as Acumen holds $128M cash - Stock Titan
Is Acumen Pharmaceuticals (ABOS) stock outpacing its medical peers this year? - MSN
How Acumen (ABOS) adapts when conditions change (Bullish Sentiment) 2026-05-08Stock Idea Sharing Hub - newser.com
Acumen Pharmaceuticals Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
Acumen Pharmaceuticals to present at Bank of America 2026 Health Care Conference on May 14. - Pluang
Acumen executives take Bank of America health care stage May 14 - Stock Titan
Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference - marketscreener.com
Acumen Pharmaceuticals (ABOS.US) will release its earnings report before the market opens on May 12. - Moomoo
How Acumen (ABOS) responds to market challenges (Breakout Watch) 2026-05-06Alpha Picks - newser.com
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026 - Weekly Voice
Acumen sets May 12 earnings update, webcast starts at 8 a.m. ET - Stock Titan
ABOS Forecast, Price Target & Analyst Ratings | ACUMEN PHARMACEUTICALS INC (NASDAQ:ABOS) - ChartMill
ABOS - Finviz
Short Interest in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Increases By 46.4% - MarketBeat
Acumen Pharmaceuticals files to sell 10.83M shares of common stock for holders - MSN
Research presented by Acumen Pharmaceuticals explores new approach at AAN meeting - Traders Union
Acumen targets ALTITUDE-AD Phase II readout in late 2026 while advancing EBD program with $36M funding - MSN
Acumen (NASDAQ: ABOS) seeks approval for major equity plan expansion - Stock Titan
Acumen Pharmaceuticals Inc Stock (ABOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acumen Pharmaceuticals Inc Stock (ABOS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Meisner Derek M | Chief Legal Officer & Corp Sec |
Mar 06 '26 |
Sale |
3.26 |
2,090 |
6,813 |
173,999 |
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):